114 related articles for article (PubMed ID: 20110173)
1. Stereoselective synthesis of desloratadine derivatives as antagonist of histamine.
Liu GZ; Xu HW; Chen GW; Wang P; Wang YN; Liu HM; Yu DQ
Bioorg Med Chem; 2010 Feb; 18(4):1626-32. PubMed ID: 20110173
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological activity evaluation of desloratadine analogues as H1 receptor antagonists.
Lin Y; Wang Y; Sima LF; Wang DH; Cao XH; Chen LG; Chen B
Bioorg Med Chem; 2013 Jul; 21(14):4178-85. PubMed ID: 23719280
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects.
Kreutner W; Hey JA; Anthes J; Barnett A; Young S; Tozzi S
Arzneimittelforschung; 2000 Apr; 50(4):345-52. PubMed ID: 10800633
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antihistamine evaluations of novel loratadine analogues.
Wang Y; Wang J; Lin Y; Si-Ma LF; Wang DH; Chen LG; Liu DK
Bioorg Med Chem Lett; 2011 Aug; 21(15):4454-6. PubMed ID: 21733682
[TBL] [Abstract][Full Text] [Related]
5. Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study).
Munoz-Cano R; Ainsua-Enrich E; Torres-Atencio I; Martin M; Sánchez-Lopez J; Bartra J; Picado C; Mullol J; Valero A
J Investig Allergol Clin Immunol; 2017; 27(3):161-168. PubMed ID: 27758758
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and antihistamine evaluations of several N-hydroxyalkyl desloratadine analogues.
Lin Y; Wang Y; Sima LF; Wang DH; Chen LG; Li L
Med Chem; 2012 Nov; 8(6):1126-32. PubMed ID: 22779794
[TBL] [Abstract][Full Text] [Related]
7. Studies on performance and sleepiness with the H1-antihistamine, desloratadine.
Nicholson AN; Handford AD; Turner C; Stone BM
Aviat Space Environ Med; 2003 Aug; 74(8):809-15. PubMed ID: 12924753
[TBL] [Abstract][Full Text] [Related]
8. [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.
Carceller E; Merlos M; Giral M; Balsa D; Almansa C; Bartrolí J; García-Rafanell J; Forn J
J Med Chem; 1994 Aug; 37(17):2697-703. PubMed ID: 7914928
[TBL] [Abstract][Full Text] [Related]
9. Verapamil, but not probenecid, co-administration can convert desloratadine to a sedating antihistamine in mice.
Katta A; Dhananjeyan M; Bykowski C; Erhardt P; Hacker M; White DB; Bachmann K
Drug Metab Lett; 2007 Jan; 1(1):7-11. PubMed ID: 19356011
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects.
Kreutner W; Hey JA; Chiu P; Barnett A
Arzneimittelforschung; 2000 May; 50(5):441-8. PubMed ID: 10858871
[TBL] [Abstract][Full Text] [Related]
11. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
12. A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo.
Popov TA; Dumitrascu D; Bachvarova A; Bocsan C; Dimitrov V; Church MK
Inflamm Res; 2006 Jun; 55(6):241-4. PubMed ID: 16955243
[TBL] [Abstract][Full Text] [Related]
13. Desloratadine inhibits human skin mast cell activation and histamine release.
Weller K; Maurer M
J Invest Dermatol; 2009 Nov; 129(11):2723-6. PubMed ID: 19516262
[No Abstract] [Full Text] [Related]
14. Physico-chemical characterization and in vitro/in vivo evaluation of loratadine:dimethyl-β-cyclodextrin inclusion complexes.
Szabados-Nacsa A; Sipos P; Martinek T; Mándity I; Blazsó G; Balogh Á; Szabó-Révész P; Aigner Z
J Pharm Biomed Anal; 2011 May; 55(2):294-300. PubMed ID: 21316895
[TBL] [Abstract][Full Text] [Related]
15. Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique.
Wang YH; Taché Y; Harris AG; Kreutner W; Daly AF; Wei JY
Allergy; 2005 Jan; 60(1):117-24. PubMed ID: 15575942
[TBL] [Abstract][Full Text] [Related]
16. Form I of desloratadine, a tricyclic antihistamine.
Bhatt PM; Desiraju GR
Acta Crystallogr C; 2006 Jun; 62(Pt 6):o362-3. PubMed ID: 16763328
[TBL] [Abstract][Full Text] [Related]
17. Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 Receptor.
Wu RL; Anthes JC; Kreutner W; Harris AG; West RE
Int Arch Allergy Immunol; 2004 Dec; 135(4):313-8. PubMed ID: 15564772
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel desloratadine derivatives with anti-inflammatory and H
Li F; Xu Q; Zhu Q; Chu Z; Lin G; Mo J; Zhao Y; Li J; He G; Xu Y
Bioorg Med Chem Lett; 2019 Dec; 29(24):126712. PubMed ID: 31679973
[TBL] [Abstract][Full Text] [Related]
19. Seizures induced by desloratadine, a second-generation antihistamine: clinical observations.
Cerminara C; El-Malhany N; Roberto D; Lo Castro A; Curatolo P
Neuropediatrics; 2013 Aug; 44(4):222-4. PubMed ID: 23456992
[TBL] [Abstract][Full Text] [Related]
20. Desloratadine partially inhibits the augmented bacterial responses in the sinuses of allergic and infected mice.
Kirtsreesakul V; Blair C; Yu X; Thompson K; Naclerio RM
Clin Exp Allergy; 2004 Oct; 34(10):1649-54. PubMed ID: 15479283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
